This trial is evaluating whether Quality-of-Life Assessment will improve 1 primary outcome, 6 secondary outcomes, and 3 other outcomes in patients with Anatomic Stage IA Breast Cancer AJCC v8. Measurement will happen over the course of Baseline.
This trial requires 249 total participants across 2 different treatment groups
This trial involves 2 different treatments. Quality-of-Life Assessment is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The most common peripheral nervous system disease in adult dogs is paroxysmal idiopathic paralysis. Most of the time, the paroxysmal attacks occur more than three times a week. Paroxysmal paralysis is more common in dogs than cats. Most cases of paroxysmal idiopathic paralysis occur in older dogs, although one case of paroxysmal idiopathic paralysis was seen in a 4-year-old Shih Tzu Poodle. Paroxysmal idiopathic paralysis can be treated with the anticonvulsant carbamazepine. It can, however, be debilitating and the dog may have to be put on a full nutritional or medical support for months." - Anonymous Online Contributor
"In a recent study, findings suggests that it is no longer correct to advocate for a cure of peripheral neuropathies. However, the patients with the neuropathic pain or the paresthesias can be treated." - Anonymous Online Contributor
"Nerve fiber disease can be caused by injury, inflammatory processes, or a toxic insult caused by a virus, autoimmune disease, or environmental stress. Nerves are not static structures, however, and will shrink, swell, twist, change color, and die over time. Nerve fiber disorders are common and are often under-diagnosed." - Anonymous Online Contributor
"Most therapies work only to manage a symptom and are poorly studied as treatments for a disease. Those treatments that are supported by clinical evidence typically target neuropathic pain, movement disorders, and spasticity. Clinical trials are needed for all new therapies, especially the ones based on the newest molecular knowledge, that are likely to be approved. summary: This article presents a selection of treatment options for specific patient groups, e.g., specific cancer-related health problems as well as common pain syndromes." - Anonymous Online Contributor
"Data from a recent study of patients with peripheral neurological disease, the majority showed signs of autonomic (possess[ing] abnormal heart rate or blood pressure (e.g. tachycardia [fastheart rate], orthostatic hypotension [low blood pressure upon standing up]) and neurogenic deficits (e.g. abnormal reflexes and sensory functions of the extremities (e.g. absent or reduced vibration)). The peripheral neurological deficit are more severe in patients with concurrent internal disorders (e.g. depression and anxiety)." - Anonymous Online Contributor
"Around 35 million people have peripheral nerve or nerve root disorders each year in the United States. Most of these cases occur before the age of 40. This makes it the most common problem in the United States among young adult Americans. Many patients who develop peripheral conditions are unaware or fail to realize the true nature of the condition before diagnosis or treatment." - Anonymous Online Contributor
"The general population may include populations who would be eligible to participate in clinical trials and in whom these risks may be acceptable to them. In any case, the general population generally has a low probability of participating in clinical trials due to limited interest in the topic and a lack of willingness or willingness not to respond." - Anonymous Online Contributor
"The quality-of-life assessment alone has an excellent likelihood of detecting moderate and substantial improvements in the patients who had undergone any treatment modality. [Power(http://www.withpower.com/d/treatments-and-side-effects/quality-of-life-assessment/quality-of-life-questionnaire/find-active-clinical-trials)()] shows the usefulness of this assessment for evaluating quality-of-life of patients with various treatments." - Anonymous Online Contributor
"The average age people develop PNS diseases are as follows: peripheral neuropathy (49.7 yr), amyotrophy, and Guillain-Barre syndrome and polyradiculopathy, all of which have an average first onset age of 49.7. This article will discuss clinical trials for peripheral neuropathy, amyotrophy, and Guillain-Barre syndrome. For polyradiculopathy this article discusses clinical trials." - Anonymous Online Contributor
"PNS diseases in families are not as common as previously thought and other neurogenic conditions should be taken into account in those patients who do not show the characteristic features of PNS diseases." - Anonymous Online Contributor
"Despite the high prevalence of depression and PNI, health-related quality of life remained unaffected by the PNI, which makes it a potentially powerful tool in the screening and early recognition of depression after serious illness." - Anonymous Online Contributor
"These studies suggest that QOL is a complex and subjective concept. The measurement in the clinical setting is highly complex and results from the combination of clinical, biological, psychological, and social factors. For that reason, the measurement of QOL should always involve a balanced set of clinical, biological, psychological, and social methods. A holistic measurement may be of benefit for a variety of clinical decisions and, ultimately, for health-care providers." - Anonymous Online Contributor